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ABSTRACT
Toxoplasmic encephalitis (TE) is the most important opportunistic infection of the central nervous
system in patients infected with human immunodeficiency virus (HIV)-1. This study evaluated the effect
of highly active anti-retroviral therapy (HAART) and Toxoplasma gondii-specific immune responses on
the occurrence of TE. The clinical characteristics of all patients diagnosed with TE in two centres since
1990 (n = 140) were analysed. Patients were grouped according to the date of diagnosis (period 1, 1990–
1993; period 2, 1994–1996; period 3, 1997 onwards). Immune responses to T. gondii were evaluated in a
subgroup (n = 12) by interferon (IFN)-c-specific ELISPOT tests. There were marked differences in the
estimated Kaplan–Meier overall survival (OS), with a 1-year OS (5-year OS) of 41% (7%) in period 1,
56% (29%) in period 2, and 90% (78%) in period 3 (p <0.0001). In period 3, TE was found to be the first
AIDS-defining illness more frequently than in earlier periods (74% vs. 38%, p 0.0002). Persistent
neurological deficits caused by TE were present in 37% of the patients. Patients with an acute episode of
TE or a TE relapse had significantly lower responses in the T. gondii-specific ELISPOT than patients who
discontinued maintenance therapy and were relapse-free (p 0.0044). Survival of HIV patients with TE
has improved markedly since the introduction of HAART, but persistent neurological deficits are often
present in surviving patients. While preventive therapy remains essential, evaluation of T. gondii-
specific immune responses may be an important step in improving estimates of the individual risk of TE
and TE relapses.
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INTRODUCTION
Although the incidence of toxoplasmic encephal-
itis (TE) has decreased since the availability of
highly active anti-retroviral therapy (HAART), TE
remains the most important opportunistic disease
of the central nervous system in patients infected
with human immunodeficiency virus (HIV) [1,2].
TE usually occurred in individuals with CD4+
T-cell counts of <100 ⁄ lL, and its prognosis was
poor in the pre-HAART era. Intra-cerebral persis-
tence of Toxoplasma gondii resulted in high relapse
rates, and life-long maintenance therapy (MT) was
thought to be required. A few cohort studies [3–5]
have suggested that it is reasonable to consider
MT discontinuation for patients who have a
sustained increase in their CD4+ T-cell counts
following the initiation of HAART [6]. However,
there have also been reports of patients develop-
ing TE relapses after discontinuation of MT
despite high CD4+ T-cell counts [7–9]. It is there-
fore important to better evaluate the restoration of
T. gondii-specific immune responses in individual
patients. Clinical studies of T. gondii-specific
immune reconstitution in patients receiving
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HAART have not been performed to date. More-
over, there are only a few studies addressing the
outcome and the evolving characteristics of TE in
the HAART era.
Accordingly, the present study investigated the
characteristics and the clinical course of all HIV-
infected patients diagnosed with toxoplasmosis
since 1990 in two large HIV centres in Germany.
To evaluate longitudinal changes in clinical char-
acteristics over time, the patients were grouped
according to the date of TE diagnosis. Among
living patients, T. gondii-specific immune
responses were measured whenever possible.
PATIENTS AND METHODS
Clinical data
This retrospective study included all HIV-1-infected patients
diagnosed with TE in two large HIV centres in Germany
between 1990 and 2004 (St Georg Hospital, Hamburg, 102
cases; University Hospital Schleswig-Holstein, Campus Kiel,
38 cases). Patients were identified from the computerised
databases at both centres. In cases where the diagnosis of
toxoplasmosis was not confirmed histologically, a presumptive
diagnosis based on the definition of the 1993 CDC classifica-
tion [10] was accepted. A presumptive diagnosis was assumed
in cases with a recent onset of clinical signs and evidence from
brain imaging (computed tomography or nuclear magnetic
resonance) and serum antibody of toxoplasmosis or successful
response to therapy for toxoplasmosis. Patients with Toxoplas-
ma chorioretinitis (n = 7) or with involvement of other organs
(n = 1) were also included in the analysis.
Data collected for all patients included demographical
characteristics, HIV and AIDS history, and the immunological,
virological, clinical, radiological and therapeutic features of TE.
Patients were grouped according to the date of TE diagnosis
(period 1, 1990–1993; period 2, 1994–1996; period 3, 1997
onwards). Period 3, which was considered to be the HAART
period, was further divided into an early HAART period (1997–
1999) and a late HAART period (2000–2004).
Immune responses
Whenever possible, blood samples were collected after
informed consent was obtained. Peripheral blood mononu-
clear cells were prepared by Ficoll–Hypaque density centrif-
ugation from heparinised blood, and were cultured in
RPMI 1640 medium supplemented with fetal calf serum 5%
v ⁄v. For flow-cytometry, peripheral blood mononuclear cells
were stained with phycoerythrin-labelled monoclonal anti-
bodies to CD4 (DakoCytomation, Hamburg, Germany) and
examined in a FACS-Calibur (Becton Dickinson, Heidelberg,
Germany). ELISPOT assays for human interferon-c were
performed using an EliSpot Assay Kit (AID, Straßberg,
Germany). In brief, 200 000 peripheral blood mononuclear
cells were cultured for 20 h at 37C in 96-well EliSpot plates
with 200 lL culture medium ⁄well. Cells were either left
unstimulated or were stimulated with anti-CD3 monoclonal
antibody (clone X35; Beckman-Coulter, Krefeld, Germany)
1 ng ⁄mL, or with T. gondii soluble antigens from tachyzoites
(Acris, Hiddenhausen, Germany) 2 lg ⁄mL, or with T. gondii
antigens supplemented with either interleukin (IL)-12 (Strath-
mann, Hamburg, Germany) 10 ng ⁄mL or IL-15 (Strathmann)
10 ng ⁄mL. The plates were then washed and treated in
consecutive incubation steps, as recommended by the kit
manufacturer, with biotinylated anti-interferon-c antibodies,
peroxidase-conjugated streptavidin, and substrate buffer (3-
amino-9-ethylcarbazole and H2O2). Visualisation and analysis
of the spots was performed using the EliSpot Reader System
ELR02 (AID). All assays were performed in duplicate and in a
blinded fashion.
Statistics
Fisher’s exact test was used for comparison of frequencies. The
Mann–Whitney test was used for unpaired comparison of
continuous variables. A p value <0.05 was considered to be
significant. Kaplan–Meier statistics were used to evaluate
overall survival (OS) and survival in different subgroups. For
comparison of survivor functions, a log-rank test was
performed. Co-variables analysed in univariate analyses
included previous AIDS-defining illnesses (yes vs. no), CD4+
T-cell count at TE diagnosis (two different cut-offs were used:
<50 ⁄ lL vs. ‡50 ⁄ lL; <100 ⁄lL vs. ‡100 ⁄lL), level of haemoglo-
bin (‡10 g ⁄dL vs. <10 g ⁄dL), lactate dehydrogenase (LDH;
‡300 U ⁄L vs. <300 U ⁄L), age (‡45 years vs. <45 years), gender,
and treatment of TE (sulphadiazine–pyrimethamine-based
regimens vs. other regimens). A multivariable Cox propor-
tional-hazards regression model was used to evaluate those
factors that were associated independently with OS.
RESULTS
In total, 140 patients (123 males, 17 females) with
TE were included in the analysis. The most
frequent risk-factor for HIV-1 infection was men
having sex with men (58%), followed by hetero-
sexual sexual exposure (14%). Only 6% of
patients reported a history of intravenous drug
use, 5% reported receipt of potentially contamin-
ated blood products, and 5% came from countries
in which HIV is endemic. The mode of infection
was unknown for 14% of the patients. The
baseline characteristics of the patients at the time
of TE are depicted in Table 1. Of note, only a few
patients had been receiving TE prophylaxis (9%)
or HAART (5%) at the time of TE diagnosis.
Some differences were observed when compar-
ing the baseline characteristics of the patients
diagnosed with TE during the pre-HAART era
with those of patients diagnosed in the HAART
era (Table 1). For example, significantly more
patients developed toxoplasmosis as the first
AIDS-defining illness after 1997. There were also
more patients for whom the period between the
first HIV test and toxoplasmosis diagnosis was
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<6 months. Although the median CD4+ T-cell
counts at the time of TE diagnosis did not differ
between the two periods, a lower proportion of
patients developed toxoplasmosis with <50 CD4+
T-cells ⁄ lL during the HAART period. There were
no significant differences with respect to age,
gender, length of time since first positive HIV test,
and mean LDH or haemoglobin levels. The type
of toxoplasmosis treatment did not change signi-
ficantly over time.
Outcome
At the final follow-up on 31 December 2004, 86 of
140 patients had died, 13 were lost to follow-up,
and 41 were alive. Of the patients who were alive
at the last follow-up and for whom detailed
information concerning health status was avail-
able, 16 ⁄ 43 (37%) patients had maintained neu-
rological deficits (hemiparesis, seizures, cognitive
or other deficits) caused by toxoplasmosis. Of
patients diagnosed with TE after 1996, the per-
centage of patients with deficits remaining was
45%.
There were marked differences in the estimated
Kaplan–Meier OS curves among the three time
periods. The estimated 1-year-OS, 2-year-OS and
5-year OS figures were 41%, 28% and 7% in
group 1, 56%, 32% and 29% in group 2, and 90%,
86% and 78% in group 3, respectively (p <0.0001,
log-rank test). There were no significant differ-
ences between the early and the late HAART
periods. The Kaplan–Meier curves for the three
periods (the HAART period was divided into an
early and a late HAART period) are shown in
Fig. 1. Survival rates did not change significantly
when patients with toxoplasmosis involving
organs other than the central nervous system
were excluded. During the initial treatment for
toxoplasmosis, a high rate of adverse events was
observed, leading to discontinuation of the initial
regimen for 55 (44%) of 125 patients. The main
reason for discontinuation was allergic reactions.
The frequency of discontinuation did not differ
among the regimens.
Risk-factors for poor OS
Several factors were found to be associated with
poor OS in univariate analysis (Table 2). OS was
significantly better in patients diagnosed after
1996, in those without a previous AIDS-defining
illness, in patients aged <45 years, and in those
with an LDH level <300 U ⁄L. A low CD4+ T-cell
count of <50 cells ⁄lL at baseline showed a trend
towards poorer OS. There were no differences in
OS with respect to gender, haemoglobin level or
TE treatment. In the multivariate Cox regression
analysis, four variables remained significantly
associated with better OS: diagnosis of TE in
1997–2004; no previous AIDS-defining illness; an
age <45 years; and an LDH level <300 U ⁄L
(Table 3).
T. gondii-specific immune response
Of 19 patients for whom the results of ELISPOT
testing were available, seven were excluded from
Table 1. Baseline characteristics at the time of diagnosis of toxoplasmic encephalitis
All 1990–1996 1997–2004 p
n 140 97 43
Female (%) 15 ⁄ 140 (11) 7 ⁄ 97 (7) 8 ⁄ 43 (19) NS
Age, years (range) 41.6 ± 10.4 41.8 ± 9.7 41.1 ± 11.9 NS
Previous AIDS diagnosis (%) 71 ⁄ 139 (51) 60 ⁄ 97 (62) 11 ⁄ 42 (26) 0.0002
Time since first positive HIV test, years 4.0 ± 3.7 3.9 ± 3.1 4.1 ± 4.9 NS
Time since first positive HIV test <6 months (%) 40 ⁄ 140 (29) 19 ⁄ 97 (20) 21 ⁄ 43 (49) 0.001
Absolute CD4+ T-cells ⁄ lL (range) 51 ± 61 (0–379) 43 ± 47 (0–300) 70 ± 80 (0–379) NS
Absolute CD4+ T-cells <50 ⁄ lL (%) 85 ⁄ 130 (65) 63 ⁄ 88 (72) 22 ⁄ 42 (52) 0.048
HIV RNA, log copies ⁄mL (range) 4.8 ± 1.1 NA 4.8 ± 1.1 NA
Toxoplasma gondii serology positive (%) 113 ⁄ 116 (97) 78 ⁄ 80 (98) 35 ⁄ 36 (97) NS
Organs other than CNS involved (%) 8 ⁄ 124 (7) 3 ⁄ 88 (3) 5 ⁄ 39 (14) NS
Mean LDH, U ⁄L 282 ± 129 296 ± 143 244 ± 72 NS
Haemoglobin level, g ⁄dL (range) 11.5 ± 1.7 11.4 ± 1.6 11.8 ± 1.8 NS
Treatment of TE
Sulphadiazine–pyrimethamine-based-treatment (%) 86 ⁄ 129 (67) 63 ⁄ 89 (71) 23 ⁄ 40 (58) NS
HAART before or at TE diagnosis (%) 8 ⁄ 134 (6) 1 ⁄ 93 (1) 7 ⁄ 41 (17) 0.001
HAART after TE (%) 58 ⁄ 137 (42) 16 ⁄ 94 (17) 42 ⁄ 43 (98) <0.0001
Residual disease in patients alive (%) 16 ⁄ 43 (37) 3 ⁄ 14 (21) 13 ⁄ 29 (45) NS
HIV, human immunodeficiency virus; LDH, lactate dehydrogenase; HAART, highly active anti-retroviral therapy; TE, toxoplasmic encephalitis; CNS, central nervous system;
NS, not significant; NA, not applicable. Values are means ± standard deviations unless otherwise indicated.
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the final analysis as they were still receiving MT
(n = 5), or because the period of relapse-free
survival after discontinuation of MT was
<12 months (n = 2). The 12 patients (11 males
and one female) who had discontinued MT for
>12 months were assigned to two groups accord-
ing to their clinical course, which indicated the
clinical evidence for either a poor or an adequate
immune response to T. gondii.
Group A (n = 5, poor response) comprised
patients who had acute episodes of TE. These
included three HAART-naive patients who pre-
sented with an acute TE and low CD4+ T-cell
counts, and two further patients who developed a
TE episode while receiving HAART. Of these two
patients, one developed a TE relapse 59 months
after the first episode, with a CD4+ T-cell count of
220 ⁄ lL, and only 4 months after discontinuation
of MT (Fig. 2, patient K1). The other patient (H1)
presented with multiple typical TE lesions despite
an absolute CD4+ T-cell count of 380 ⁄lL (relative
30%). This patient did not receive TE prophylaxis
and had also presented with two episodes of
oesophageal candidiasis a few months earlier. At
the time of the TE episode, both patients receiving
HAART had a plasma viraemia level below the
limit of detection (for at least 45 and 18 months,
respectively) and a CD4+ T-cell count of >200 ⁄ lL
(for at least 7 months and 58 months, respect-
ively).
Group B (n = 7, adequate response) included
patients who had discontinued MT at least
12 months previously and who had not
developed a TE relapse for at least 12 months
(median 40, range 13–63 months). Six patients
discontinued MT after sustained immune recon-
stitution, and one patient (K4; Fig. 2) discontinued
MT because of highly elevated liver enzymes in
the context of chronic hepatitis B co-infection.
The details of the ELISPOT results for each
patient are shown in Fig. 2. Group A patients had
a significantly lower number of spots in the
T. gondii-stimulated cultures, with a median of 3
(range, 1–6) vs. 25.5 (7.5–63) spots for group B
patients (p for two-tailed Mann–Whitney test,
0.0044). This was also the case when IL-12- and
IL-15-stimulated cultures were analysed; the
median numbers of spots in the IL-12- and
IL-15-stimulated cultures were 4 (1–11) and 13
(5.5–20) spots for group A vs. 27 (18–79, p 0.008)
and 48 (23–87, p 0.0045) spots, respectively, for
group B.
DISCUSSION
Although the incidence of TE has reduced
markedly in the HAART era [1], this disease
remains the most important neurological oppor-
tunistic infection in HIV-infected patients [2,11].
The data presented in this study indicate that
several characteristics of this disease have chang-
ed since the introduction of HAART, and that the
situation of an HIV-infected patient developing
toxoplasmosis during recent years differs from
that of a patient during earlier years of the
epidemic. As shown previously [11,12], patients
presenting with toxoplasmosis in the HAART era
do not usually receive anti-retroviral therapy or
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Fig. 1. Cumulative overall survival of patients diagnosed
with toxoplasmic encephalitis at different time periods.
Table 2. Factors associated with better overall survival in
univariate analysis
Factor p
No previous AIDS-defining illness (vs. yes) <0.0001
Diagnosis of TE 1997–2004 (vs. 1990–1996) 0.003
Age at TE <45 years (vs. >45 years) <0.0001
CD4+ T-cell counts ‡50 ⁄ lL (vs. <50 ⁄ lL) 0.056
LDH <300 U ⁄L (vs. ‡300 U ⁄L) 0.026
HAART after TE (vs. no HAART after TE)a <0.0001
LDH, lactate dehydrogenase; HAART, highly active anti-retroviral therapy; TE,
toxoplasmic encephalitis.
aAs almost all patients with a diagnosis of TE in 1997–2004 received HAART after
TE, HAART was not included in the Cox model.
Table 3. Remaining variables for overall survival in the
Cox model
RH (95% CI) p
No previous AIDS-defining illness (vs. yes) 0.33 (0.18–0.61) 0.0005
Diagnosis of TE in 1997–2004 (vs. 1990–1996) 0.27 (0.11–0.64) 0.0032
Age at TE <45 years (vs. >45 years) 0.49 (0.29–0.84) 0.0086
LDH <300 U ⁄L (vs. ‡300 U ⁄L) 0.53 (0.31–0.93) 0.0260
LDH, lactate dehydrogenase; RH, relative hazard; TE, toxoplasmic encephalitis.
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any prophylaxis. Such patients are likely to be
diagnosed with HIV at the time of TE diagnosis,
and TE is now more frequently the first AIDS-
defining illness in these patients than during the
pre-HAART era.
The prognosis of patients with TE has also
improved markedly since the introduction of
HAART. Although the potential effect of better
supportive care or other factors during recent
years could not be excluded, this may be mainly
an effect of HAART, as the standards for induc-
tion and MT for toxoplasmosis did not change
over time at the study sites. However, it seems
important that the prognosis of patients with TE
did not continue to improve during the late
HAART era. Toxoplasmosis remains a potentially
life-threatening disease and acute management
may be critical. This is also underlined by the
observation of high rates of toxicity of induction
therapies in this cohort, as has also been found in
prospective clinical trials [13–16].
Despite some limitations associated with the
retrospective design of this study, the results
indicate that the use of HAART after diagnosis of
toxoplasmosis remains the most important factor
in TE treatment, apparently dominating the long-
term efficacy of various specific treatments for
T. gondii. There is growing evidence that func-
tional immune restoration during HAART in
patients with advanced HIV-1 disease may be
incomplete [17–19]. With respect to the specific
response to T. gondii, one cross-sectional study
[20] and one prospective study (10th Conference
on Retroviruses and Opportunistic Infections,
Boston, MA, USA; abstract 796) have shown that
antigen-specific responses may be restored incom-
pletely in a substantial number of patients with
sustained CD4+ T-cell increases while receiving
HAART. Thus, evaluating the T. gondii-specific
response could be important in evaluating an
individual’s risk of TE and TE relapses. The
present study found that the ELISPOT technique
was helpful in this setting. Patients with an acute
TE episode had a significantly lower specific
response to T. gondii than patients who had
discontinued MT and remained relapse-free.
There have been several reports of patients
developing TE or other opportunistic infections
despite high CD4+ T-cell counts [7–9,21–23].
These reports, and the present data, indicate that
quantitative increases in CD4+ T-cells may not
always reflect the quality of antigen-specific
responses. Of note, there was also one patient
who had discontinued MT because of a toxicity
reaction and who was relapse-free for 13 months,
despite a CD4+ T-cell count that was consistently
<200 ⁄ lL, indicating that the T. gondii-specific
immune responses were adequate.
There were some limitations to the present
study. The lesions were not proven histologically,
and the number of patients was too small to allow
the proposal of a clear cut-off value to discrimin-
ate among patients with sufficient and insufficient
T. gondii-specific immune responses. T. gondii-
specific immune responses were not studied in
HIV-seronegative individuals or in patients with
no episodes of TE. However, although the data
concerning specific immune responses are lim-
ited, they indicate that an antigen-specific ELI-
SPOT could be helpful in stratifying the risk of the
recurrence of TE in T. gondii antibody-positive
patients with HIV infection. Further prospective
studies should evaluate ELISPOT tests as a tool to
decide whether MT for chronic TE should be
continued or could be safely discontinued.
In conclusion, TE currently occurs mainly in
untreated patients presenting with advanced HIV
infection. Although the prognosis of TE has
improved markedly in the HAART era, neuro-
logical deficits are still frequently present, and
thus prevention of TE remains essential. Evaluat-
ing T. gondii-specific immune responses may be
an important step towards better estimating the
individual risk of TE and TE relapses.
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